These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1267 related items for PubMed ID: 23556551

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
    Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sánchez-Pobre P, Cosme A, Ortiz V, Niño P, Khorrami S, Benito LM, Carneros JA, Lamas E, Modolell I, Franco A, Ortuño J, Rodrigo L, García-Durán F, O'Callaghan E, Ponce J, Valer MP, Calvet X, H. pylori Study Group of the Asociación Española de Gastroenterología.
    Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
    Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M, Rodrigo L, Ortuño J, Sánchez-Pobre P, Khorrami S, Franco A, Tomas A, Guerra I, Lamas E, Ponce J, Calvet X, H. pylori Study Group of the Asociación Española de Gastroenterología (Spanish Gastroenterology Association).
    J Clin Gastroenterol; 2013 Feb; 47(2):130-5. PubMed ID: 22647827
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.
    Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X.
    Aliment Pharmacol Ther; 2012 Apr; 35(8):941-7. PubMed ID: 22372560
    [Abstract] [Full Text] [Related]

  • 9. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC, Taiwan Acid-Related Disease (TARD) Study Group.
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [Abstract] [Full Text] [Related]

  • 10. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP.
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. First-line triple therapy with levofloxacin for Helicobacter pylori eradication.
    Gisbert JP, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, Robledo-Andrés P, González-García G.
    Aliment Pharmacol Ther; 2007 Aug 01; 26(3):495-500. PubMed ID: 17635384
    [Abstract] [Full Text] [Related]

  • 17. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N, Miyake K, Kusunoki M, Shindo T, Kawagoe T, Futagami S, Tsukui T, Inagaki H, Sakamoto C.
    Helicobacter; 2009 Apr 01; 14(2):91-9. PubMed ID: 19298336
    [Abstract] [Full Text] [Related]

  • 18. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
    Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D'Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P.
    Clin Res Hepatol Gastroenterol; 2013 Dec 01; 37(6):647-50. PubMed ID: 23747131
    [Abstract] [Full Text] [Related]

  • 19. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.
    Dig Liver Dis; 2016 May 01; 48(5):506-511. PubMed ID: 26847964
    [Abstract] [Full Text] [Related]

  • 20. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D, Almeida N, Gregório C, Cabral JE, Casela A, Donato MM, Tomé L.
    BMC Gastroenterol; 2017 Feb 15; 17(1):31. PubMed ID: 28202013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.